

Biallelic variants in the small optic lobe calpain *CAPN15* are associated with congenital eye anomalies, deafness and other neurodevelopmental deficits.

Congyao Zha^{1,12}, Carole A Farah^{1,12}, Richard J Holt², Fabiola Ceroni², Lama AlAbdi^{3,4}, Fanny Thuriot⁵, Arif O Khan^{6,7,8}, Rana Helaby⁴, Sébastien Lévesque⁵, Fowzan S Alkuraya^{4,9}, Alison Kraus¹⁰, Nicola Ragge^{2,11,13} and Wayne S Sossin^{1,13*}

¹*Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, H3A 2B4*

²*Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, UK*

³*College of Science, King Saud University, Riyadh, Saudi Arabia*

⁴*Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia*

⁵*Department of Pediatrics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada*

⁶*Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia*

⁷*Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates*

⁸*Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine at Case Western University, Cleveland, Ohio, USA*

⁹*Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia*

¹⁰*Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX*

¹¹*West Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Foundation Trust, Birmingham, B15 2TG, UK*

¹²Equally contributed

¹³Joint last authors

*Corresponding author: Wayne Sossin. Montreal Neurological Institute, 3801 University Avenue, Montreal, Quebec, CANADA H3Z-2H3; Phone: 1-514-398-1486; Fax 1-514-398-8106; Email: wayne.sossin@mcgill.ca

Abstract

Microphthalmia, coloboma and cataract are part of a spectrum of developmental eye disorders in humans affecting ~12 per 100,000 live births. Currently, variants in over 100 genes are known to underlie these conditions. However, at least 40% of affected individuals remain without a clinical genetic diagnosis, suggesting variants in additional genes may be responsible. Calpain 15 (CAPN15) is an intracellular cysteine protease belonging to the non-classical Small Optic Lobe (SOL) family of calpains, an important class of developmental proteins, as yet uncharacterised in vertebrates. We identified five individuals with microphthalmia and/or coloboma from four independent families carrying homozygous or compound heterozygous predicted damaging variants in *CAPN15*. Several individuals had additional phenotypes including growth deficits, developmental delay and hearing loss. We generated *Capn15* knockout mice that exhibited similar severe developmental eye defects, including anophthalmia, microphthalmia, and cataract, and diminished growth. We demonstrate widespread *Capn15* expression throughout the brain and central nervous system,

strongest during early development, and decreasing postnatally. Together, these findings demonstrate a critical role of *CAPN15* in vertebrate developmental eye disorders, and may signify a new developmental pathway.

Introduction

Developmental eye anomalies, including anophthalmia (absent eye), microphthalmia (small eye) and coloboma (disruption of the optic fissure closure), collectively known as AMC, are a genetically heterogeneous group of disorders affecting between 11.9 and 30 per 100,000 live births(1). Single gene alterations can underlie these conditions, the most frequent being in *SOX2*(2). To date, ~100 genes have been consistently associated with these phenotypes and are included in standard structural eye disorders diagnostic panels (<https://panelapp.genomicsengland.co.uk/panels/509/>). Data for congenital cataracts are similar, with an estimated prevalence of 1.91 to 4.24 per 10,000 children (3) and nearly 100 genes considered diagnostic (<https://panelapp.genomicsengland.co.uk/panels/230/>). There is a degree of genetic overlap in the underlying causes of AMC and cataract, as seen with variants in *GJA8* (4). However, at least 40% of individuals with AMC (depending on phenotype) remain without a genetic diagnosis (2, 5), indicating that additional unidentified genetic factors contribute to these conditions.

Calpains are intracellular cysteine proteases(6) with important roles in development. There are four conserved families: Classical, PalB, Transformer (Tra), and Small Optic Lobe (SOL), with ‘Classical’ being the best characterized. All calpain isoforms have a conserved catalytic domain and each family is characterized by unique domains: a C-terminal penta-EF

hand domain in Classical calpains; a C-terminal C2 domain in Tra calpains; an N-terminal MIT domain and an additional C-terminal C2-like domain in PalB calpains, and an N-terminal zinc finger domain that binds polyubiquitin(7) and a C-terminal SOL homology domain (SOLH) in SOL calpains(8, 9).

Embryonic mice with a homozygous disruption of the murine Classical calpain small subunit gene *Capn4* (causing disruption of the activities of Classical calpains Capn1 and Capn2) die midgestation, displaying defects in the cardiovascular system, hemorrhage, and accumulation of erythroid progenitors(10). Furthermore, pre-implantation embryonic lethality between the morula and blastocyst stage is observed in mice with a homozygous *Capn2* deletion (11). Tra-3 (Transformer 3) calpain was first discovered in the nematode *C. elegans*, as a sex determination gene(12). Later, studies suggested that Tra-3 cleaves Tra-2, which then interacts with transcription factor Tra-1 both directly and indirectly to promote female development(13, 14). In addition, *C. elegans* with a single nucleotide polymorphism in Tra-3 displayed a smaller body size when animals were grown at low temperature(15). In humans, variants in the orthologue of the Tra calpain (*CAPN5*) that hyperactivate its protease activity are associated with inflammatory vitreoretinopathy, hearing loss and developmental delay (16).

An atypical calpain, *CAPN15* (also known as *SOLH* or *SOL calpain*) is located on chromosome 16p13.3(17), a region previously implicated in inherited cataracts with microphthalmia(18). It was first characterized in the fruit fly *Drosophila*(19, 20), where loss of SOL calpain leads to a 50% reduction in the volume of the optic lobes due to degeneration and absence of certain classes of columnar neurons(20). In *Aplysia*, the orthologue of

CAPN15 is required for the induction of long-term plasticity implicated in non-associative memory, but not the long-term plasticity implicated in associative memory (21, 22).

Using whole exome sequencing (WES) we identified five individuals from four independent families with likely pathogenic homozygous or compound heterozygous variants in *CAPN15*, displaying microphthalmia and/or coloboma plus additional phenotypes including growth delay. To characterize the role of CAPN15 in vertebrates, we generated a *Capn15* knockout mouse. *Capn15*^(-/-) mice displayed developmental eye anomalies including anophthalmia, microphthalmia and cataract, as well as reduced body weight similar to our affected individuals. Our data shows that *CAPN15* plays a critical role in eye development and growth in vertebrates. It is the first intracellular protease linked to AMC, indicating a new pathway and is an important gene to include on diagnostic gene panels for developmental eye disorders and cataract.

Results

Identification of five individuals with CAPN15 mutations and eye anomalies

WES of 55 individuals with developmental eye disorders from a UK cohort (Supplemental Methods) identified one individual with unilateral microphthalmia and bilateral coloboma with a previously unreported homozygous missense variant in *CAPN15* exon 13 (NM_005632.2:c.2905G>A; NP_005623.1:p.(Gly969Ser); chr16:602863 [hg19]) (Individual 1) (Figure 1A). Subsequently, four additional individuals with AMC spectrum disorders and biallelic *CAPN15* variants from three independent families were identified by WES. Individual 2, recruited to the Deciphering Developmental Disorders (DDD) project, was identified with compound heterozygous *CAPN15* variants. The first variant was a paternally inherited missense variant in exon 8 (NM_005632:c.2159C>T; NP_005623.1:p.(Ser720Phe);

chr16:601394 [hg19]), absent from the gnomAD database (<http://gnomad.broadinstitute.org/>)(23). The second variant was a rare maternally inherited missense variant in exon 10 (rs762523863; NM_005632:c.2398C>T; NP_005623.1:p.(Arg800Trp); gnomAD minor allele frequency = 0.00001986) (chr16:602103 [hg19]) (Figure 1B). Individual 3 carries a homozygous missense variant in *CAPN15* exon 13 (NM_005632.3:c.3083G>A; p.(Arg1028Lys); chr16: 603041 [hg19]) absent from the gnomAD database(23) (Figure 1C). Finally, individuals 4 and 5, siblings and offspring of distantly related parents, were ascertained through a Canadian cohort of 51 patients presenting with anomalies, with or without neurodevelopmental disorders (24). They harbour a homozygous missense variant in *CAPN15* exon 6 (NM_005632.3:c.1838C>T; NP_005623.1:p.(Ser613Leu); chr16:599467 [hg19]) (Figure 1D). This variant is extremely rare, reported in only 3 individuals on the gnomAD database (minor allele frequency 0.00001421), with no individuals with homozygosity for this variant observed. All five variants are predicted damaging by SIFT(25) and PolyPhen-2(26) and were validated by Sanger sequencing. In each case, the identified variants were inherited from asymptomatic heterozygous parents with no family history of eye anomalies. The siblings of Individual 1 were found to be asymptomatic heterozygous carriers. No genotyping data is available for the unaffected sibling of Individuals 4 and 5. The segregation of disease with biallelic *CAPN15* variants in these five families confirms a recessive pattern of inheritance. No other likely pathogenic variants in known AMC genes were identified in these individuals by WES.

Detailed phenotypic descriptions of each individual are provided in Table 1, Figure 2 and the Supplemental Results. All five affected individuals presented with AMC spectrum disorders; two individuals (1 and 2) had microphthalmia, four had coloboma (1, 3, 4, and 5), and Individual 1 also had a unilateral lens opacity (cataract). Interestingly, some individuals

showed additional delay in growth and development. Three individuals showed delayed growth, including short stature (1, 2, and 4), low weight (1 and 2), reduced head circumference (1 and 2) and clinical microcephaly affecting Individual 4. Furthermore, Individuals 2, 4 and 5 presented with developmental delay, in addition to cognitive delay (2) and autism (2 and 5). Finally, three individuals (2, 4 and 5) were diagnosed with hearing loss and both Individuals 2 and 4 had simple external ear features. It is also interesting to note the presence of multiple miscarriages in Family 1.

As the c.2905G>A (Individual 1) and c.3083G>A (Individual 3) variants affect the first and last nucleotides of *CAPN15* exon 13, respectively, we investigated their impact on splicing. For c.2905G>A we generated cDNA from blood samples from Individual 1 and their parents. However, PCR and Sanger sequencing across exons 11-14 revealed no alteration in splicing (data available on request). Similarly, for Individual 3 we observed no impact on splicing after performing RTPCR on RNA extracted from LCLs derived from this patient (data available on request).

Within *CAPN15*, all five variants are located within the C-terminal portion of the protein and affect amino acids conserved across multiple vertebrate species (Figure 3). However, only p.(Ser613Leu) (Individuals 4 and 5) and p.(Ser720Phe) (Individual 2) are located within an annotated region of the protein, both lying within the Calpain catalytic domain. As no 3D structure for *CAPN15* is available, we used I-TASSER (27-29) to generate a predicted structure. Site Directed Mutator (SDM; <http://marid.bioc.cam.ac.uk/sdm2/prediction>) was applied to this model to predict the impact of the variants on *CAPN15* stability (Table 2). This indicated that p.(Gly969Ser) and p.(Arg1028Lys) may decrease protein stability ($\Delta\Delta G = -3.27$ and -1.15 , respectively), whereas p.(Ser613Leu) is predicted to increase stability ($\Delta\Delta G$

= 1.85). Interestingly, both of the mutations predicted to decrease CAPN15 stability are in the highly conserved SOLH domain that is present only in SOL calpains and whose structure and function is unknown.

Capn15^(-/-) mice have anophthalmia, microphthalmia and cataract

The protein encoded by the human CAPN15 gene (NP_005623.1) has 87.4% identity/90.9% similarity to the mouse orthologue NP_001334263 using EMBOSS Needle (30). Mouse embryonic stem cells with a *lacZ*-Neo cassette inserted into the *Capn15* locus were obtained from the International Mouse Phenotyping Consortium (IMPC)(31) and used to generate *Capn15* knockout mice (Supplemental Figure 1A). Disruption of *Capn15* was confirmed by Western blotting of brain homogenates using an antibody raised against the C-terminal of the protein (Supplemental Figure 1B).

In a cross of *Capn15* heterozygous mice, the incidence of *Capn15^(-/-)* pups was 12%, significantly lower than the expected 25% (12%, $p=1.28e^{-5}$, Chi Square test; WT n=52, *Capn15^{+/-}* n=155, *Capn15^{-/-}* n=29). This indicates that homozygous loss of the gene results in decreased viability, and is of further interest given the presence of multiple miscarriages in Family 1. Furthermore, *Capn15^(-/-)* mice that were successfully weaned weighed 11% (+/-3% SEM) less than their littermate WT or heterozygous mice ($p=0.003$ and $p=0.0006$, respectively. Student's t-test; WT n=45, *Capn15^{+/-}* n=71, *Capn15^{-/-}* n=18), recapitulating the delayed growth and development in several of our affected individuals (Figure 4A). Most significantly, homozygous *Capn15* KO mice displayed a range of developmental eye disorders overlapping those observed in the 5 affected individuals with biallelic *CAPN15* variants. These included anophthalmia (18%), microphthalmia (26%) and cataract (31%) (Figure 4B-E). Less than 6% of heterozygous mice overall displayed developmental eye

disorders (anophthalmia 1%, microphthalmia 2%, and cataract in 2%). No significant difference was observed between the left and right eyes of adult *Capn15* KO mice (>12 weeks of age) ($p=0.15$) and there was no preference for bilateral or unilateral presentation. Therefore, after pooling left and right eyes, the presence of these phenotypes was significantly increased in *Capn15* KO mice compared to heterozygous or WT mice ($***p<0.0001$; WT n=30, *Capn15*^{+/-} n=160, *Capn15*^{-/-} n=90 including offspring from parents who were both *Capn15*^{-/-}; Figure 4F). This difference in eye phenotype was present in mice at 6 and 12 weeks of age, suggesting that these anomalies were the result of aberrant development.

Capn15 is highly expressed in the brain and eye

To investigate the role of *Capn15* in the brain during development, *lacZ* expression was examined in *Capn15*^(lacZ-Neo) heterozygous mice. X-gal staining of sagittal sections of E12 embryos showed that *Capn15* was primarily expressed in the outer layer of the central nervous system, in particular the mantle zone of the pallium and subpallium (forebrain), and the mantle zone of the rhombomere (hindbrain) (Figure 5A). At E18 *Capn15* was expressed widely in the nervous system with high levels in the subventricular zone, immediately next to the ventricular zone. Expression was strongest in the deep cortical layer of the cerebral cortex, and neuroepithelium layer in the hippocampus, but not the pyramidal layer. By P3, *Capn15* was ubiquitously expressed in the brain from the olfactory bulb to the cerebellum and also within the retina, particularly in the ganglion cell layer (Figure 5C-D). To further explore the pattern of expression over time, *Capn15* protein expression in the rat brain was examined over time using immunoblotting. Here, expression was found to be highest during embryonic development (E14-E18 brains), decreasing significantly after birth (P0-adult) (Figure 5E, F).

Discussion

Our data demonstrate the importance of the protease *CAPN15* in mammalian eye and brain development. We identified likely pathogenic recessively inherited variants in five individuals with AMC and/or cataract and additional phenotypes including delayed growth and development. These phenotypes were recapitulated in a mouse model, with further data supporting expression of the gene during brain development.

Our cases showed microphthalmia and/or coloboma, while 18% of knockout mice had the more severe anophthalmia. The milder phenotypic range displayed in the humans may be explained by all five variants being missense. These variants could impact protein function by destabilising protein structure, affecting the calpain catalytic activity, or its regulation by the SOLH domain. This is likely to be less damaging to overall function than the total loss of the gene in the mouse knockout. This may also account for the presence of AMC phenotypes at low frequency in heterozygous mice, which were not detected in humans heterozygous for the missense variants. Alternatively, it may reflect the small sample group of humans or interspecies variation. However, given the lack of a functional assay for *CAPN15*, it is difficult to determine whether the variability between mouse and human phenotypes and/or amongst the individuals carrying distinct missense changes is due to different effects of these variants on the protein. The penetrance of the eye phenotype in the mouse was also variable, even with a complete knockout, suggesting a complex relationship between the loss of *CAPN15* and the eye phenotype. Therefore, screening of additional individuals with AMC would help to determine both the full phenotypic range associated with variants in this gene, as well as potential genotype-phenotype correlations. Furthermore, only Individual 1 had cataract, while 31% of mice had this phenotype. This may reflect ascertainment bias, as none

of the participants or cohorts included in this study was recruited on the basis of this phenotype. However, recent reports show that variants in *GJA8*, a gene associated with isolated cataract, are also a significant cause of microphthalmia, accounting for over 1% of cases of AMC in large cohorts (4).

Developmental delay and hearing loss were present in three individuals with *CAPN15* variants. Our data shows strong embryonic expression of *Capn15* in the brain, suggesting that it is important in neurodevelopment. Therefore, the *CAPN15* variants may underlie these phenotypes as well as eye anomalies. Similarly, growth delay was observed in three individuals and the *Capn15*^{-/-} mice also exhibited a significant growth deficit.

There is little known about the function of the SOL calpain family, of which CAPN15 is the sole human member. This family diverged from other calpain families before the origin of metazoans and is conserved in all metazoans, suggesting a fundamental role for the protein (9). Two of the identified variants are in conserved residues in the calpain catalytic domain present in all members of the calpain family, while a third variant lies adjacent to it. However, while the N-terminal of the SOL calpain has been shown to bind to poly-ubiquitin(7), there have been no functional studies on the calpain or *SOLH* domain of this family of genes. In *Drosophila*, the large loss of neurons in the optic lobe was thought to be due to degeneration(20), but a role for Capn15 in early differentiation during development was not excluded. In *Aplysia*, SOL calpain is important for the induction of plasticity associated with non-associative learning(21), perhaps due to cleavage of Protein Kinase Cs (PKCs) into persistently active Protein Kinase Ms (PKMs)(7, 32). Further investigation of how Capn15 performs these functions may also shed light on its role during eye development. Furthermore, as other calpains function to regulate transcription through

regulated cleavage of transcription factors (33), and since many genes underlying ocular anomalies are transcription factors(2), investigation of the role CAPN15 plays in early developmental transcriptional pathways may also prove a valuable avenue of research.

Together, our data meet criteria for inclusion of *CAPN15* in clinical genetic diagnostic testing for AMC according to both the Clinical Genome Resource (ClinGen) (www.clinicalgenome.org)(34, 35) and Genomics England PanelApp (<https://panelapp.genomicsengland.co.uk/#!/Guidelines>). Therefore, these data will contribute to improved care for AMC patients and their families.

Conclusions

We demonstrate for the first time the importance of *CAPN15* in mammalian eye development, identifying likely pathogenic variants in five individuals with AMC from four families, supported by a mouse KO model and embryonic expression studies. These findings translate to clinical benefit by adding a new gene to clinical diagnostic testing, and potentially a new pathway in the increasingly complex network involved in human eye development.

Materials and Methods

Ethics approval and consent to participate

The UK cohort of 316 individuals with ocular anomalies was recruited as part of a national ‘Genetics of Eye and Brain anomalies’ study (REC 04/Q0104/129). Informed consent was obtained according to the tenets of the Declaration of Helsinki. Individual 2 was recruited into the Deciphering Developmental Disorders (DDD) Study, which has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). For individual 3, informed written consent was obtained from all participants under an IRB approved protocol (KFSHRC RAC# 2070023).

Individuals 4 and 5 are members of a Canadian study approved by the institutional ethics review board of Université de Sherbrooke (project 12–167). All participants or their legal guardians provided written consent. All studies on mice were approved by the Montreal Neurological Institute/McGill University Animal care and use committee protocol 2009–5784

***Capn15* antibody**

Polyclonal antibodies were raised in rabbits against the carboxy terminal of Capn15 using the following epitope: CDVAGLHGPRPL. A cysteine residue was added to the N-terminal of the peptide to enhance coupling. Peptides were coupled to KLH-maleimide and SulfoLink coupling resin (Thermo Fisher Scientific) according to manufacturer’s instruction. After conjugation to KLH-maleimide, rabbits were injected and after four boosts the final serum was affinity purified on SulfoLink columns as previously described(36).

Generation of a Capn15 KO mouse

We obtained embryonic stem cells with a *lacZ*-Neo cassette inserted into the mouse *Capn15* locus from the International Mouse Phenotyping Consortium (IMPC)(31). The strategy used by the consortium was to insert a cassette that provides a strong exon entry site coupled with a stop codon, with *lacZ* produced from internal ribosome entry site translation (31, 37). To remove this cassette, these mice were bred with mice that contain flippase (FLP) recombinase that recognizes a pair of FLP recombinase target (FRT) sequences that flank the genomic region containing this cassette leaving lox sites surrounding the calpain catalytic domain exons 4-6 (based on NCBI reference sequence NM_001347334.1). These mice were then bred against mice expressing germline Cre recombinase to remove the floxed exons and generate a KO line (Supplemental Figure 1).

Dissections

Adult mice were transcardially perfused with ice-cold phosphate-buffered saline (PBS) followed by 4% (wt/vol) ice-cold paraformaldehyde (PFA) in PBS. Brains were post-fixed in 4% PFA for 45min at 4°C, rinsed in PBS, and cryoprotected in 30% sucrose/PBS overnight at 4°C. The following day, brains were embedded in Tissue-PlusTM O.C.T. compound (Fisher Healthcare) and flash frozen in 2-methylbutane chilled in dry ice. The brains were kept at -80°C until further use.

X-gal staining

Sections of 20µm were incubated overnight at 37°C in solution containing 80 mM Na₂HPO₄, 20 mM NaH₂PO₄, 2 mM MgSO₄, 5 mM K₃[Fe(CN)₆], 5 mM K₄[Fe(CN)₆], 0.2% NP-40, 0.1% sodium deoxycholate, and 1.5 mg/ml X-gal. Sections were rinsed in PBS, washed in ethanol (50% for 1min, 70% for 1min, 95% for 1min and 100% for 2X1min), cleared in xylene, and mounted with Permount (Thermo Fisher Scientific).

Western blotting

Embryonic brains were homogenized manually in lysis buffer containing 25 mM Tris-HCl (pH 7.4), 150 mM NaCl, 6 mM MgCl₂, 2 mM EDTA, 1.25% NP-40, 0.125% SDS, 25 mM NaF, 2 mM Na₄P₂O₇, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 20 mg/ml leupeptin, and 4 mg/ml aprotinin. Before loading, 5X sample buffer was added to the lysate and samples were incubated at 95°C for 5min. Proteins were resolved by SDS-PAGE on Bis-Tris gel and transferred to nitrocellulose membrane (Bio-Rad). The blots were blocked in TBST (TBS + 0.1% Tween) containing 4% skim milk for 30min at room temperature and then incubated with primary antibodies overnight at 4°C. After washing 3 times with TBST, the blots were incubated with HRP-conjugated secondary antibodies for 1 hour at RT, and washed again 3 times in TBST. The Western Lightning Plus-ECL kit (NEL103001EA; PerkinElmer LLC Waltham, MA USA) was used as per manufacturer's instructions to detect protein bands. The primary antibody used was homemade rabbit anti-Capn15 antibody (1:1000) raised against the C-terminus of Capn15. The secondary antibody was horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:5000). Antibodies were diluted in Tris buffered saline with Tween containing 4% skim milk powder.

Eye phenotype quantification

Mice eyes were examined and grouped as follows: seems normal, obvious cataract, small eye and no eye. This categorisation was performed for both eyes of each mouse. The analysis was performed without the knowledge of the genotype of the mice.

Quantification of immunoblotting

Immunoblots were scanned and imaged using the public domain Image J program developed at the U.S. National Institute of Health (<https://imagej.nih.gov/ij/>). We calibrated our data with the uncalibrated optical density feature of NIH image, which transforms the data using the formula $\log_{10}[\frac{\text{---}}{\text{---}}]$, where x is the pixel value (0–254). We used the Ponceau image for each gel to normalize the amount of SOL calpain in brains at different ages to the amount of SOL calpain in E12-E14 brains run on the same gel.

Whole Exome Sequencing

A UK cohort of 316 individuals with ocular anomalies, principally AMC, was recruited as part of a national ‘Genetics of Eye and Brain anomalies’ study (REC 04/Q0104/129). Informed consent was obtained according to the tenets of the Declaration of Helsinki. Patients were screened by indication in known AMC genes. Fifty-five individuals from the cohort were screened by whole exome sequencing (WES) as described previously(38, 39). Individual 2 was recruited into the Deciphering Developmental Disorders (DDD) Study, which has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC).

For individual 3, WES was performed as previously described (40). Sanger sequencing and segregation analysis were completed. Informed written consent was obtained from all participants under an IRB approved protocol (KFSHRC RAC# 2070023).

Individuals 4 and 5 are siblings who were identified through whole-exome sequencing of a Canadian cohort of 51 patients presenting dysmorphisms with or without neurodevelopmental disorders (24).

The following primers were used for sequencing: For Individual 1: Forward Primer CCATCATCCTGCTCACCGA and Reverse Primer GGCACGCTATCCTGGGTAC; For Individual 2 Exon 8: Forward Primer GCAACATGAAGGTGGACGAT and Reverse Primer AGCTGCCGTTCCAGGAGAAA; For Individual 2 Exon 10: Forward Primer GGAGGGCTTCCTATTATAGG and Reverse Primer AACACCAGGATGCACAGGTC and For Individual 3: Forward Primer GCAGGGGTCCCGAGA and Reverse Primer CAGACCGGCGACCTCT.

cDNA and splicing studies

Blood samples were collected from Individual 1 and her parents, RNA was extracted using a RNeasy Mini kit (Qiagen) and cDNA generated using a high capacity reverse transcriptase kit (Applied Biosystems). To examine the impact of the variant on splicing, forward and reverse PCR primers were designed mapping to exons 11 and 14, respectively (Forward: GTCAAGAAGTTCGTCAGCTG, Reverse: CTGTCCAGTCACTGAGGAAG).

Acknowledgements

This work was supported by CIHR grant MOP 340328 to WSS as well as by grants from Baillie Gifford, Microphthalmia, Anophthalmia and Coloboma Support (MACS) (www.macs.org.uk), HEIF (Health Innovation Fund, Oxford Brookes University), King Salman Center for Disability Research (FSA), Researchers Supporting Project number (RSP-2020/181), King Saud University, Riyadh, Saudi Arabia, institutional funds of the Université de Sherbrooke, La Fondation du Grand Défi Pierre Lavoie, and La Fondation des Étoiles. We would like to thank the families for their participation in our study. The authors would also like to thank Mireille Bouchard-Levasseur for excellent technical assistance in quantification of the transgenic mice eye phenotype, Dr. Len Levine for advice concerning the eye phenotype, Dr. Zvi Gan-Or for initial assistance in human genomics, the West Midlands Regional Clinical Genetics Service for their help with sample processing and clinical genetic testing of UK families with AMC conditions, Dr. Dorine Bax, Oxford Brookes University, Oxford for research coordination, the Sequencing and Genotyping Core Facilities at KFSRHC for their technical help, the support of the Saudi Human Genome Program, Niema Ibrahim for her help as a clinical coordinator, and Annabelle Pratte, genetic counsellor, for her help with clinical information of individuals 4 and 5. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003]. This study makes use of DECIPHER (<http://decipher.sanger.ac.uk/>), which is funded by Wellcome. See Nature PMID: 25533962 (https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_pubmed_-3Fterm-3D25533962&d=DwIF-g&c=D7ByGjS34AllFgcyw0iC6Zq7qlm8uclZFI0SqQnqBo&r=4KNgiByx5ZDuuQKe7_F5cAmmY9GaslfHYZ8UCyouNzY&m=3qfQbvTNwcqZG71zAHbbAJmPgTH7167rrFR5RarH7e0&s=vT_eWJBaUeCuN2e1yYLyBVP9xBuUJbqAtscisWeG0ns&e=))

or <http://www.ddduk.org/access.html> (<http://www.ddduk.org/access.html>) for full
acknowledgement.

Conflicts of Interest

The authors state no conflicts of interest in this study.

References

- 1 Campbell, H., Holmes, E., MacDonald, S., Morrison, D. and Jones, I. (2002) A capture-recapture model to estimate prevalence of children born in Scotland with developmental eye defects. *J. Cancer Epidemiol. Prev.*, **7**, 21-28.
- 2 Plaisancie, J., Ceroni, F., Holt, R., Zazo Seco, C., Calvas, P., Chassaing, N. and Ragge, N.K. (2019) Genetics of anophthalmia and microphthalmia. Part 1: Non-syndromic anophthalmia/microphthalmia. *Hum. Gene.t*, **138**, 799-830.
- 3 Wu, X., Long, E., Lin, H. and Liu, Y. (2016) Prevalence and epidemiological characteristics of congenital cataract: a systematic review and meta-analysis. *Sci Rep.*, **6**, 28564.
- 4 Ceroni, F., Aguilera-Garcia, D., Chassaing, N., Bax, D.A., Blanco-Kelly, F., Ramos, P., Tarilonte, M., Villaverde, C., da Silva, L.R.J., Ballesta-Martinez, M.J. *et al.* (2019) New GJA8 variants and phenotypes highlight its critical role in a broad spectrum of eye anomalies. *Hum. Genet.*, **138**, 1027-1042.
- 5 Patel, N., Khan, A.O., Alshahli, S., Abdel-Salam, G., Nowilaty, S.R., Mansour, A.M., Nabil, A., Al-Owain, M., Sogati, S., Salih, M.A. *et al.* (2018) Genetic investigation of 93 families with microphthalmia or posterior microphthalmos. *Clin. Gene.t*, **93**, 1210-1222.
- 6 Guroff, G. (1964) A Neutral, Calcium-Activated Proteinase from the Soluble Fraction of Rat Brain. *J. Biol. Chem.*, **239**, 149-155.
- 7 Hastings, M.H., Qiu, A., Zha, C., Farah, C.A., Mahdid, Y., Ferguson, L. and Sossin, W.S. (2018) The zinc fingers of the small optic lobes calpain bind polyubiquitin. *J. Neurochem.*, **146**, 429-445.
- 8 Zhao, S., Liang, Z., Demko, V., Wilson, R., Johansen, W., Olsen, O.A. and Shalchian-Tabrizi, K. (2012) Massive expansion of the calpain gene family in unicellular eukaryotes. *BMC Evol. Biol.*, **12**, 193.
- 9 Hastings, M.H., Gong, K., Freibauer, A., Courchesne, C., Fan, X. and Sossin, W.S. (2017) Novel calpain families and novel mechanisms for calpain regulation in Aplysia. *PLoS One*, **12**, e0186646.
- 10 Arthur, J.S. and Elce, J.S. (2000) Fluorescence measurements of Ca²⁺ binding to domain VI of calpain. *Methods Mol. Biol.*, **144**, 121-127.
- 11 Dutt, P., Croall, D.E., Arthur, J.S., Veyra, T.D., Williams, K., Elce, J.S. and Greer, P.A. (2006) m-Calpain is required for preimplantation embryonic development in mice. *BMC Dev. Biol.*, **6**, 3.
- 12 Hodgkin, J.A. and Brenner, S. (1977) Mutations causing transformation of sexual phenotype in the nematode *Caenorhabditis elegans*. *Genetics*, **86**, 275-287.
- 13 Sokol, S.B. and Kuwabara, P.E. (2000) Proteolysis in *Caenorhabditis elegans* sex determination: cleavage of TRA-2A by TRA-3. *Genes Dev.*, **14**, 901-906.
- 14 Wang, S. and Kimble, J. (2001) The TRA-1 transcription factor binds TRA-2 to regulate sexual fates in *Caenorhabditis elegans*. *EMBO J.*, **20**, 1363-1372.
- 15 Kammenga, J.E., Doroszuk, A., Riksen, J.A., Hazendonk, E., Spiridon, L., Petrescu, A.J., Tijsterman, M., Plasterk, R.H. and Bakker, J. (2007) A *Caenorhabditis elegans* wild type defies the temperature-size rule owing to a single nucleotide polymorphism in *tra-3*. *PLoS Genet.*, **3**, e34.
- 16 Velez, G., Bassuk, A.G., Schaefer, K.A., Brooks, B., Gakhar, L., Mahajan, M., Kahn, P., Tsang, S.H., Ferguson, P.J. and Mahajan, V.B. (2018) A novel de novo CAPN5 mutation in a patient with inflammatory vitreoretinopathy, hearing loss, and developmental delay. *Cold Spring Harb Mol. Case Stud.*, **4**.
- 17 Kamei, M., Webb, G.C., Young, I.G. and Campbell, H.D. (1998) SOLH, a human homologue of the *Drosophila melanogaster* small optic lobes gene is a member of the calpain and zinc-finger gene families and maps to human chromosome 16p13.3 near CATM (cataract with microphthalmia). *Genomics*, **51**, 197-206.

- 18 Yokoyama, Y., Narahara, K., Tsuji, K., Ninomiya, S. and Seino, Y. (1992) Autosomal dominant congenital cataract and microphthalmia associated with a familial t(2;16) translocation. *Hum. Genet.*, **90**, 177-178.
- 19 Delaney, S.J., Hayward, D.C., Barleben, F., Fischbach, K.F. and Miklos, G.L. (1991) Molecular cloning and analysis of small optic lobes, a structural brain gene of *Drosophila melanogaster*. *Proc. Natl. Acad. Sci. U. S. A.*, **88**, 7214-7218.
- 20 Fischbach, K.F. and Heisenberg, M. (1981) Structural brain mutant of *Drosophila melanogaster* with reduced cell number in the medulla cortex and with normal optomotor yaw response. *Proc. Natl. Acad. Sci. U. S. A.*, **78**, 1105-1109.
- 21 Hu, J., Adler, K., Farah, C.A., Hastings, M.H., Sossin, W.S. and Schacher, S. (2017) Cell-Specific PKM Isoforms Contribute to the Maintenance of Different Forms of Persistent Long-Term Synaptic Plasticity. *J. Neurosci.*, **37**, 2746-2763.
- 22 Hu, J., Ferguson, L., Adler, K., Farah, C.A., Hastings, M.H., Sossin, W.S. and Schacher, S. (2017) Selective Erasure of Distinct Forms of Long-Term Synaptic Plasticity Underlying Different Forms of Memory in the Same Postsynaptic Neuron. *Curr. Biol.*, **27**, 1888-1899 e1884.
- 23 Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B. *et al.* (2016) Analysis of protein-coding genetic variation in 60,706 humans. *Nature*, **536**, 285-291.
- 24 Thuriot, F., Buote, C., Gravel, E., Chenier, S., Desilets, V., Maranda, B., Waters, P.J., Jacques, P.E. and Levesque, S. (2018) Clinical validity of phenotype-driven analysis software PhenoVar as a diagnostic aid for clinical geneticists in the interpretation of whole-exome sequencing data. *Genet. Med.*, **20**, 942-949.
- 25 Ng, P.C. and Henikoff, S. (2003) SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res.*, **31**, 3812-3814.
- 26 Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S. and Sunyaev, S.R. (2010) A method and server for predicting damaging missense mutations. *Nat. Methods*, **7**, 248-249.
- 27 Roy, A., Kucukural, A. and Zhang, Y. (2010) I-TASSER: a unified platform for automated protein structure and function prediction. *Nat. Protoc.*, **5**, 725-738.
- 28 Yang, J., Yan, R., Roy, A., Xu, D., Poisson, J. and Zhang, Y. (2015) The I-TASSER Suite: protein structure and function prediction. *Nat. Methods*, **12**, 7-8.
- 29 Yang, J. and Zhang, Y. (2015) I-TASSER server: new development for protein structure and function predictions. *Nucleic Acids Res.*, **43**, W174-181.
- 30 Needleman, S.B. and Wunsch, C.D. (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. *J. Mol. Biol.*, **48**, 443-453.
- 31 Brown, S.D. and Moore, M.W. (2012) The International Mouse Phenotyping Consortium: past and future perspectives on mouse phenotyping. *Mamm. Genome*, **23**, 632-640.
- 32 Farah, C.A., Hastings, M.H., Dunn, T.W., Gong, K., Baker-Andresen, D. and Sossin, W.S. (2017) A PKM generated by calpain cleavage of a classical PKC is required for activity-dependent intermediate-term facilitation in the presynaptic sensory neuron of *Aplysia*. *Learn. Mem.*, **24**, 1-13.
- 33 Ono, Y. and Sorimachi, H. (2012) Calpains: an elaborate proteolytic system. *Biochim. Biophys. Acta*, **1824**, 224-236.
- 34 Bean, L.J.H., Funke, B., Carlston, C.M., Gannon, J.L., Kantarci, S., Krock, B.L., Zhang, S., Bayrak-Toydemir, P. and on behalf of the, A.L.Q.A.C. (2019) Diagnostic gene sequencing panels: from design to report-a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet. Med.*, in press.
- 35 Strande, N.T., Riggs, E.R., Buchanan, A.H., Ceyhan-Birsoy, O., DiStefano, M., Dwight, S.S., Goldstein, J., Ghosh, R., Seifert, B.A., Sneddon, T.P. *et al.* (2017) Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. *Am. J. Hum. Genet.*, **100**, 895-906.

- 36 Sossin, W.S. (2003) Phosphopeptide-specific antibodies to protein kinase C. *Methods Mol. Biol.*, **233**, 233-244.
- 37 Skarnes, W.C., Rosen, B., West, A.P., Koutsourakis, M., Bushell, W., Iyer, V., Mujica, A.O., Thomas, M., Harrow, J., Cox, T. *et al.* (2011) A conditional knockout resource for the genome-wide study of mouse gene function. *Nature*, **474**, 337-342.
- 38 Holt, R.J., Young, R.M., Crespo, B., Ceroni, F., Curry, C.J., Bellacchio, E., Bax, D.A., Ciolfi, A., Simon, M., Fagerberg, C.R. *et al.* (2019) De Novo Missense Variants in FBXW11 Cause Diverse Developmental Phenotypes Including Brain, Eye, and Digit Anomalies. *Am. J. Hum. Genet.*, **105**, 640-657.
- 39 Ragge, N., Isidor, B., Bitoun, P., Odent, S., Giurgea, I., Cogne, B., Deb, W., Vincent, M., Le Gall, J., Morton, J. *et al.* (2019) Expanding the phenotype of the X-linked BCOR microphthalmia syndromes. *Hum. Genet.*, **138**, 1051-1069.
- 40 Saudi Mendeliome, G. (2015) Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases. *Genome Biol.*, **16**, 134.

Figure Legends




Figure 1. Pedigrees of the five Individuals with *CAPN15* variants. Chromatograms of Sanger sequencing validation of the variants in affected individuals shown. Position of variant indicated in red. Note that sequencing for Individual 3 was performed from cDNA.
(A) Individual 1 **(B)** Individual 2 **(C)** Individual 3 **(D)** Individuals 4 and 5.




Figure 2. Phenotypes of Individuals 1, 3 and 4. (A) Right iris and chorioretinal coloboma, and left mild microphthalmia with an iris and chorioretinal coloboma involving the disc in Individual 1. (B, C) Inferonasal chorioretinal coloboma (B) and iris coloboma of the right eye (C) in Individual 3. (D) Bilateral iris and chorioretinal coloboma (more prominent in the left eye), and dysmorphic features including left ptosis, left simple ear, and prominent columella in Individual 4.




Figure 3. Schematic of CAPN15 showing the location of the variants identified in Individuals 1-5. Zinc fingers shown in red, the calpain catalytic domain in blue and the SOLH domain in green. The conservation of the affected amino acids in human, mouse, chicken, *Xenopus* and zebrafish is indicated.




Figure 4. *Capn15* KO mice display growth and eye anomalies (A) Mean weights of *Capn15* KO and *Capn15* heterozygous mice after weaning normalized to the mean weight of WT mice. Error bars represent SEM. (B-E) Representative photographs of the eye phenotypes of *Capn15* KO mice; normal (B), anophthalmia (C), microphthalmia (D) and cataract (E). (F) Comparison of the percentage of eye anomalies in WT, *Capn15*

heterozygous and *Capn15* KO mice at more than 12 weeks of age. ** = $p=0.003$, *** = $p=0.0006$.




Figure 5. *Capn15* is enriched in rodent brain and eyes during early development. (A-D) X-gal staining of sections from E12, E18 and P3 *Capn15*^(lacZ-Neo) heterozygous mice. Scale

bar is 200 μ m. (A) Sagittal section of whole embryo at E12 showing *Capn15* expression in the mantle zones of the pallium, subpallium, and rhombomere. (B) Coronal section of the brain at E18 showing expression in the cerebral cortex, hippocampus. (C) Coronal section of the brain at P3 showing generalised expression, including the hippocampus. (D) Sagittal section of the eye at P3, highlighting expression in the ganglion cells of the retina. (E) Western blots using protein extracts from rat brains at E14, E18, P0, P30 and P \geq 60 showing decreasing *Capn15* expression with increasing age. Experiment was performed in triplicate. (F) Quantification of *Capn15* expression in rat brain. *Capn15* expression was normalized to E12-E14 brains; E12-E14 n=3, E16-E18 n=4, P0-P5 n=4, P30 n=2, and P \geq 60 n=3. Error bars represent SEM. Abbreviations: C (cortex), G (ganglion cell layer), Hi (hippocampus), Hy (hypothalamus), MZP (mantle zone of pallium), MZR (mantle zone of rhombomere), MZS (mantle zone of subpallium), P (photoreceptor cell layer).

Table 1: Phenotypes of the five human individuals identified carrying homozygous or compound heterozygous *CAPN15* variants. Individuals 4 and 5 are siblings. y (years).

Individual	1	2	3	4	5
Variant	p.(Gly969Ser)	p.(Ser720Phe) p.(Arg800Trp)	p.(Arg1028Lys)	p.(Ser613Leu)	p.(Ser613Leu)
Eye	Unilateral microphthalmia, bilateral coloboma, unilateral lens opacity	Bilateral microphthalmia, iridio-corneal adhesions	Bilateral myopia, unilateral coloboma	Bilateral coloboma, unilateral ptosis	Unilateral coloboma
Growth	Poor weight gain	Delayed	Normal	Short stature	Normal
Developmental delay	Normal	Cognitive delay, autism	Normal	Global delay	Developmental delay, autism spectrum disorder

Head circumference	19 th % (3.5y)	5 th % (14y)	Normal	Microcephaly	Normal
Hearing	Normal	Hearing loss	Normal	Deaf	Deaf
Other	Laryngeal cleft, dysphonia, hirsute, sacral dimple	Bicuspid aortic valve, horseshoe kidney, simple ears, unusually shaped small pituitary	-	Facial dysmorphism, imperforate anus, unilateral simple ear, prominent columella	Imperforate anus with vaginal fistula, hemivertebrae

Table 2: Site Directed Mutator (SDM; <http://marid.bioc.cam.ac.uk/sdm2/prediction>) analysis of the impact of CAPN15 variants on protein stability.

Variant	$\Delta\Delta G$	Stability
p.S613L	1.85	Increased
p.S720F	0.52	Increased
p.R800W	0.24	Increased
p.G969S	-3.27	Reduced
p.R1028K	-1.15	Reduced